Clinical Trials Browser

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06134375 2026-04-20

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

204 enrolled

Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

96 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual

NCT05232916 2026-03-19

FLAMINGO-01

Phase 3 Recruiting

750 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

119 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

976 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual

NCT07025785 2026-01-15

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Phase NA Recruiting

100 enrolled

Breast

Breast Neoplasms, Lymphatic Metastasis, Neoplasm, Residual

NCT03945721 2025-09-29

UNITY

Phase 1 Active not recruiting

21 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04674306 2025-05-23

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

Phase EARLY_PHASE1 Active not recruiting

35 enrolled

Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04130152 2022-10-25

PROMETEO II

Phase EARLY_PHASE1 Completed

22 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual

NCT01401959 2018-06-15

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

Phase 2 Completed

127 enrolled 11 charts

Breast

Breast Neoplasms, Neoplasm, Residual

Clinical Trials

PREDICT-RD

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

PALAVY

FLAMINGO-01

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

MiRaDoR

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

UNITY

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

PROMETEO II

Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy